Lessons from regulatory agilities during the COVID-19 pandemic: views from members of National Regulatory Authorities
To address the COVID-19 pandemic, regulatory agilities were allowed and utilized by National Regulatory Authorities (NRAs) in an unprecedented manner to accelerate the development, assessment, and approval of medicines and vaccines. Since 2021,
the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) has been exploring common regulatory agilities utilized during the early phases of the pandemic alongside related experiences, challenges, and lessons learned, to explore how regulatory processes might be further enhanced in the future
in both non-emergency and emergency situations.
This report aims to explore the perspective of members of NRAs on the use of regulatory agilities which emerged during the COVID-19 pandemic and describe lessons learnt from this experience. Insights were collected via interviews with members of NRAs from Brazil, Ghana, and Japan, thus gathering views from different regions. Understanding the views of NRA members on regulatory agilities can help to develop realistic approaches to strengthen both non-emergency and emergency regulatory frameworks moving forward. The insights included in this report reflect the personal views of the individuals interviewed and are not representative of the position of any specific NRA.
Downloads
Related news and resources
How we are contributing to global pharmaceutical standards
The evolving global pharmaceutical regulatory environment and the increasing interest of new countries in joining the ICH highlights the importance of maintaining consistent interpretation and implementation of ICH guidelines among industry and regulatory authorities worldwide. The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), along with other ICH Members and Observers, has an important role...
Read more
Regulatory agilities applied to vaccines during the COVID-19 pandemic and recommendations for the future
This position paper outlines some key regulatory agilities implemented in areas such as research and development, regulatory evaluations, authorizations, and post-approval changes (PACs) and labelling. Key learnings and recommendations to enhance regulatory frameworks in the future are also included.
Read more
Industry perspectives on implementation of Quality Overall Summary-Product Dossier (QOS-PD) and Quality Information Summary (QIS) for innovative medicinal products
In view of a growing complexity of product lifecycle management, industry puts forward perspectives to support the harmonization of regulatory requirements. These are intended to facilitate efficient regulatory review and approval to support timely implementation of changes and product improvements, leading to more resilient supply chains.
Read more